title: [Risk Factors of Recurrent Bleedings at Therapeutic International Normalized Ratio in Patients on Long-Term Warfarin Therapy].
abstract: OBJECTIVE
  to investigate parameters of fibrinolysis in patients on long-term warfarin (W) therapy, and assess their relation to the risk of recurrent bleeding occurring at therapeutic international normalized ratio (INR).
  
  
  METHODS
  Our prospective study involved 78 W-naive patients (40 men, age 64.3+/-12.2 years). Follow up period was 5.6+/-3.4 months. INR was measured monthly; determination of coagulation parameters (D-dimer, fibrinogen, complex plasmin-2-antiplasmin [PAP] and thrombin-activatable fibrinolysis inhibitor [TAFI] was performed before and after at least 3 months of W therapy.
  
  
  RESULTS
  During follow-up bleedings occurred in 47 (60.3%) patients, 26 patients (33.3%) had recurrent bleedings at therapeutic INR and 21 patients (26.9%) had single bleeding. Mean time in therapeutic range (TTR) was >70.
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Moreva
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.
authors.forename: E S
authors.initials: ES
authors.lastname: Kropacheva
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.
authors.forename: A B
authors.initials: AB
authors.lastname: Dobrovolsky
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Titaeva
authors.affiliation: Institute of Cardiology of Russian Cardiology Scientific and Production Complex, Moscow, Russia.
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001777:Blood Coagulation; D005338:Fibrin Fibrinogen Degradation Products; D005341:Fibrinolysin; D006470:Hemorrhage; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D012307:Risk Factors; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin
chemical_list: D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D014859:Warfarin; D005341:Fibrinolysin